A polyketide compound, preparation method and application

Abstract

This invention presents a polyketide compound, its preparation method, and its applications. The polyketide compound Dinemasone D was isolated from the solid-state fermentation product of *Phaeosphaeria poagena*. The polyketide compound Dinemasone D obtained in this invention exhibits a strong inhibitory effect on lipopolysaccharide (LPS)-induced NO production in BV-2 microglia, with an IC50 value of [missing value]. 50 The value was 13.8 ± 0.4 μM, close to the level of quercetin.

Description

Technical Field

[0001] This invention relates to the field of biomedical technology, and in particular to a polyketide compound, its preparation method, and its application. Background Technology

[0002] Neurodegenerative diseases (NDs), such as Alzheimer's disease (AD), Parkinson's disease, and Huntington's disease, are a complex group of progressive and incurable diseases characterized by the loss and gradual degeneration of neurons within the central nervous system (CNS). With the aging of the global population, the incidence of neurodegenerative diseases is rapidly increasing, and a large unmet medical need remains due to the lack of effective treatments. Neuroinflammation is a defense mechanism involving responses from all cell types in the CNS. Recent discoveries of persistent neuroinflammation suggest it may be associated with the onset or early progression of Alzheimer's disease. Chronic neuroinflammation is associated with dysregulation of inflammatory mediators, excessive activation of microglia, and subsequent neurodegeneration. Therefore, inhibiting chronic neuroinflammation induced by microglia activation may be an effective therapeutic strategy to slow the progression of neurodegenerative diseases. In recent years, the exploration of natural products with the potential to improve and treat neurodegenerative diseases has attracted widespread attention.

[0003] *Phaeosphaeria* is a genus of microfilamentous fungi belonging to the family *Phaeosphaeriaceae*. Most species in *Phaeosphaeria* are pathogens of weeds and grasses, causing serious infections, particularly on major crops such as maize and wheat. However, some *Phaeosphaeria* fungi produce structurally unique and bioactive natural products, including thiodikepiperazine, naphthoquinones, anthraquinones, diterpenoids, and isocoumarins. In the search for novel bioactive metabolites from fungi, for example, the ethyl acetate extract of *Phaeosphaeria poagena*, isolated from the roots of *Kadsura longipedunculata* Finet & Gagnep, has been found to possess anti-inflammatory activity. Summary of the Invention

[0004] In view of the above, the main objective of this invention is to provide a polyketide compound, its preparation method, and its application to solve the aforementioned technical problems.

[0005] This invention proposes a polyketide compound, the structural formula of which is as follows: .

[0006] The present invention also proposes a method for preparing a polyketide compound, wherein the method is used to prepare the above-mentioned polyketide compound, characterized in that the polyketide compound Dinemasone D is isolated from the solid fermentation product of Phaeosphaeria poagena.

[0007] The present invention also proposes an application of a polyketide compound, which is prepared by the above-described method for preparing polyketide compounds, and the polyketide compound is used to prepare an antineuritis drug.

[0008] The present invention also proposes an antineuritis drug, wherein the drug comprises a polyketide compound prepared by the above-mentioned method for preparing polyketide compounds and a pharmaceutically acceptable carrier or excipient.

[0009] Compared with the prior art, the beneficial effects of the present invention are as follows: 1) This invention is the first to obtain a polyketide compound from the genus *Phaeosphaeria poagena*, and evaluates the in vitro anti-neuroinflammatory activity of this polyketide compound from *Phaeosphaeria poagena*. The results show that the polyketide compound Dinemasone D from *Phaeosphaeria poagena* has a strong inhibitory effect on the ability of lipopolysaccharide (LPS)-induced NO production in BV-2 microglia, with an IC50 value of [missing value]. 50 The value was 13.8 ± 0.4 μM, close to the level of quercetin.

[0010] 2) Western blotting (WB) and molecular docking showed that the compound Dinemasone D exhibited moderate anti-neuroinflammatory activity, possibly by inhibiting the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2).

[0011] Additional aspects and advantages of the invention will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by means of embodiments of the invention. Attached Figure Description

[0012] Figure 1 The structural formula of the polyketide compound of this invention is shown below; Figure 2 The key to the polyketide compounds of this invention 1 H- 1 H COSY and HMBC related diagrams; Figure 3 This is a key NOESY correlation diagram for the polyketide compounds of this invention; Figure 4The experimental ECD and calculated ECD correlation diagrams for the polyketide compounds of this invention are shown. Figure 5 The polyketide compounds of this invention 1 H-NMR spectrum; Figure 6 The polyketide compounds of this invention 13 C-NMR spectrum; Figure 7 The polyketide compounds of this invention 1 H- 1 H COSY spectrum; Figure 8 The HSQC spectra of the polyketide compounds of this invention are shown below. Figure 9 This is the HMBC spectrum of the polyketide compounds of this invention; Figure 10 The NOESY spectrum of the polyketide compounds of this invention; Figure 11 The HRESIMS spectra of the polyketide compounds of this invention are shown below. Figure 12 The ultraviolet spectrum of the polyketide compounds of this invention is shown below. Figure 13 The infrared spectrum of the polyketide compounds of this invention; Figure 14 This is a graph showing the protein expression levels and quantitative analysis of iNOS and COX-2 in the polyketide compounds of this invention.

[0013] Figure 15 This is a three-dimensional molecular docking model diagram of the polyketide compounds of this invention. Detailed Implementation

[0014] Embodiments of the present invention are described in detail below. Examples of these embodiments are shown in the accompanying drawings, wherein the same or similar reference numerals denote the same or similar elements or elements having the same or similar functions throughout. The embodiments described below with reference to the accompanying drawings are exemplary and are only used to explain the present invention, and should not be construed as limiting the present invention.

[0015] These and other aspects of the embodiments of the present invention will become clear from the following description and accompanying drawings. In these descriptions and drawings, some specific embodiments of the present invention are specifically disclosed to illustrate some ways of implementing the principles of the embodiments of the present invention; however, it should be understood that the scope of the embodiments of the present invention is not limited thereto.

[0016] The experimental materials are as follows: Strains: The polyketide compounds of this invention were isolated from the solid-state fermentation product of a strain of Phaeosphaeria poagena. Phaeosphaeria poagena was purchased from Jingbaiou Biotechnology Co., Ltd.

[0017] The preservation and activation culture conditions for the genus *Phaeosphaeria poagena* were as follows: The culture was preserved using PDA slant agar. For activation, the culture was inoculated into PDA plates and incubated at 28°C for 7 days until the plates were covered with mycelium.

[0018] Experimental materials Culture medium: Solid rice culture medium: 40.00 g rice, 60.00 mL water, natural pH; autoclave the culture medium at 121℃ for 30 min before use.

[0019] PDA plate medium: Each liter of medium contains 200 g potato, 20 g glucose, and 16 g agar powder. (Solid rice medium: 40.00 g rice, 60.00 mL water, natural pH; the medium should be autoclaved at 121℃ for 30 min before use.)

[0020] PDB medium: 1.05 g potato glucose broth, 30 mL deionized water, autoclaved at 121℃ for 30 min.

[0021] PDA plate medium: Each liter of medium contains 200 g potato, 20 g glucose, and 16 g agar powder. Experimental reagents: Methanol, acetone, and chloroform are all industrial-grade reagents and are used after redistillation; ethyl acetate and petroleum ether are analytical-grade reagents; organic solvents such as chromatographic acetonitrile, DMSO, and chromatographic methanol are used according to the actual situation, using analytical-grade or chromatographic-grade reagents.

[0022] Preparation of vanillin-sulfuric acid colorimetric reagent for thin-layer chromatography (TLC): Slowly add 80 mL of concentrated sulfuric acid to 200 g of ice while stirring. Then, take 5 g of vanillin and put it into 100 mL of anhydrous ethanol and stir until dissolved. Add the dissolved vanillin-anhydrous ethanol solution to the ice water.

[0023] Experimental apparatus: Nuclear magnetic resonance spectrometer: Agilent DD2 400-MR (TMS internal standard); High performance liquid chromatography-high resolution mass spectrometry system: ABSciex Triple TOF ®4600; Polarimeter: Rudolph Autopol Ⅲ MCP5300; High Performance Liquid Chromatograph: Waters 1525 and Arc HPLC analytical type; Ultraviolet Spectrometer: Shimadzu UV-2550; Circular Dichroism Spectrometer: ChirascanCD; Microplate Reader: Synergy neo2; Fungal Incubator: BSD-TX345; Rotary Evaporator: Büchi Rotavapor R-100; Circulating Water Multi-purpose Vacuum Pump: SHB-Ⅲ (Zhengzhou Changcheng Science & Industry Trade Co., Ltd.); Low Temperature Coolant Circulating Pump: DLSB-10 / 20 (Zhengzhou Changcheng Science & Industry Trade Co., Ltd.); Clean Bench: SW-OJ-2F (Suzhou Antai Air Technology Co., Ltd., Suzhou Jingjing Group); Vertical Steam Sterilizer: BKQ-B12011 (Shanghai Boxun Industrial Co., Ltd. Medical Equipment Factory).

[0024] Liquid chromatography column: Waters XBridge C18 column (19 mm × 250 mm, 5 μm); column chromatography silica gel (100-200 mesh, 200-300 mesh and 300-400 mesh) and thin layer chromatography silica gel (silica gel H) were all produced by Qingdao Marine Chemical Plant; hydroxypropyl dextran gel Sephadex LH-20 was produced by GE Healthcare Life Sciences; RP-C18 reversed-phase silica gel was produced by YMC.

[0025] This embodiment provides a method for preparing polyketide compounds: the method includes the following steps: 1. Large-scale fermentation culture of *Phaeosphaeria poagena*: The strain was cultured on a large scale using a solid rice culture medium. The specific steps are as follows: S1. Preparation of solid rice culture medium: Add 40 g of rice and 60 mL of deionized water to each of 220 500 mL Erlenmeyer flasks, seal with a breathable membrane, and sterilize in an autoclave (121℃, 30 min). Cool for later use. S2, PDB culture medium preparation: Add 1.05 g potato glucose broth and 30 mL deionized water to each of the six 50 mL Erlenmeyer flasks. After sealing with a breathable membrane, sterilize in an autoclave (121℃, 30 min). Then, place all Erlenmeyer flasks in a clean bench and sterilize with a UV lamp for 15 min. S3. Seed culture preparation: Phaeosphaeria poagena mycelium was inoculated into PDB medium, with about 1 cm² mycelium per bottle. After labeling, the mycelium was placed in a constant temperature shaker for 5 days (28℃, 120 rpm). S4. Under aseptic conditions, 400 μL of seed culture was inoculated into each of 220 500 mL Erlenmeyer flasks of solid rice culture medium and statically cultured at 28 °C for 56 days.

[0026] 2. The specific extraction and separation methods are as follows: After large-scale fermentation, an equal volume of methanol was added to all 500 mL Erlenmeyer flasks to stop fermentation. The solid rice culture medium-methanol solution was transferred to a 30 L plastic container and ultrasonically extracted for 30 min using a large ultrasonic instrument. The mixture was then filtered through a Buchner funnel. The residue was transferred back to the plastic container, and methanol was added. The extraction was repeated three more times. All extracts were combined and concentrated under reduced pressure using a large rotary evaporator until no more methanol was distilled off. The alcohol content of the distilled methanol was measured. If the alcohol content was greater than 80% (v / v), the methanol could be reused. After concentration, a crude extract was obtained. The crude extract was dissolved in water and extracted five times with an equal volume of ethyl acetate. The supernatant was collected and concentrated by rotary evaporation to obtain an ethyl acetate extract.

[0027] Crude fraction: The ethyl acetate phase extract was subjected to silica gel column chromatography using 100-200 mesh silica gel and gradient elution with petroleum ether-acetone volume ratios of 30:1, 20:1, 10:1, 5:1, 1:1 and 0:1 to obtain five fractions (Fr. 1-Fr. 5).

[0028] Fr. 3 (10 g) was further separated by silica gel column chromatography using 200-300 mesh silica gel and gradient elution with petroleum ether-ethyl acetate volume ratio of 15:1 to 1:1 to obtain eight subfractions (Fr. 3.1-Fr. 3.8).

[0029] Gel filtration: The subfraction Fr. 3.5 (1.41 g) was separated by Sephadex LH-20 gel column chromatography, eluted isocratically with dichloromethane-methanol (volume ratio 1:1), the fractions were collected, and the fractions were combined by TLC to obtain the fraction rich in the target compound.

[0030] Purification: The fractions rich in the target compound were purified by silica gel column chromatography (300-400 mesh) with isocratic elution in petroleum ether-ethyl acetate (5:1 v / v). The fractions were collected and combined by TLC analysis. This fraction was then purified by semi-preparative high-performance liquid chromatography (HPLC) using a Waters XBridge C18 column (19 mm × 250 mm, 5 μm) and acetonitrile-water (30:70 v / v). The peak with a retention time of 24.4 min was collected, and the solvent was evaporated under reduced pressure to obtain pure compound Dinemasone D (93.0 mg).

[0031] The chemical structural formula of the polyketide compound Dinemasone D is as follows: .

[0032] The molecular formula of polyketides is C2. 12 H 16 O5 was named Dinemasone D.

[0033] To verify the chemical properties and anti-neuroinflammatory activity of the present invention, the polyketide compounds prepared in Example 1 were measured and their anti-neuroinflammatory activity was evaluated, as follows: Determination of the physicochemical properties of compounds; The physicochemical properties of the polyketide compound Dinemasone D are as follows: The molecular formula is: C 12 H 16 O5, colorless oil.

[0034] Specific rotation: [α]D 20 = -28.9 (c = 0.09, MeOH).

[0035] UV absorption: UV (CH3OH) λmax (log ε) 215 (0.55); 244 (2.27) nm, UV spectrum see Figure 12 .

[0036] Infrared absorption: IR (KBr) νmax 3321, 2934, 2837, 1676, 1640, 1449, 1413, 1088, 1021, 959 cm⁻¹ -1 Infrared spectrum (see) Figure 13 .

[0037] High-resolution mass spectrometry: HR-ESI-MS m / z 263.0888 [M+Na] + (calcd for C 12 H 16 O5Na, 263.0890), mass spectrum see Figure 11 .

[0038] 1 H-NMR (400MHz, CDCl3) and 13 Detailed data for C-NMR (100MHz, CDCl3) are shown in Table 1; 1 See H-NMR spectrum Figure 5 , 13 C-NMR spectra can be seen Figure 6 , 1 H- 1 See the H COSY diagram. Figure 7 See HSQC chart Figure 8 See HMBC chart Figure 9 See NOESY chart Figure 10 .

[0039] Table 1. Polyketide compound Dinemasone D 1 H, 13 C NMR data (CDCl3);

[0040] In the process of compound structure identification, the key 1 H- 1 H COSY and HMBC related as follows Figure 2 As shown, key NOESY related information is as follows: Figure 3 As shown, the correlation between experimental ECD and calculated ECD is as follows: Figure 4 As shown.

[0041] Determination of planar structure: The molecular formula was determined to be C using HRESIMS. 12 H 16 O5 has an unsaturation degree of 5. (Combined) 1 H- and 13 The C-NMR spectrum (Table 1) shows that the compound contains a carbonyl carbon (δ¹⁸O). C 168.4, C-5), four hydroxymethyl groups, two double bonds, and two methyl groups. (Through...) 1 H- 1 The HCOSY spectrum can identify three spin-coupled systems: H-2 / H-3 / H-4, H-7 / H2-8, and H-10 / H-11 / H-12. Figure 2 In the HMBC spectrum, the correlations between H-4 and C-4a, C-5, and C-8a, and between H2-8 and C-7, C-8a, and C-4a, constructed a 6 / 5 bicyclic skeleton containing a lactone ring and a tetrahydrofuran ring (with oxygen bridges at the 4a and 8a positions). The correlations between H-2 and C-10, and between H-10 and C-2, determined that the side chains of C-10 / C-11 / C-12 are attached at the C-2 position. This confirmed the planar structure of the compound as follows: Figure 1 As shown.

[0042] Determination of stereochemistry: The relative configuration of the compound was determined by NOESY spectroscopy. Figure 3In the NOESY spectra, a correlation exists between H-4 and H2-8, suggesting that H-4 and the C-8 methylene group are on the same side; while the strong NOESY correlation between H-2 and H-3, and the NOESY correlation between H-3 and H-4, indicate that H-2, H-3, and H-4 are in a cis relationship. The correlation between H-7 and H-9 indicates that the methyl group (H-9) is on the same side as H-7.

[0043] By comparing the experimental ECD spectrum of compound Dinemasone D with the ECD spectra of different enantiomers based on quantum chemical calculations ( Figure 4 The experimental ECD curves showed good agreement with the calculated curves for the (2R,3R,4S,7S) configuration, thus confirming the absolute configuration of the compound as 2R,3R,4S,7S. The complete structure of the compound was thus confirmed.

[0044] Evaluation of the in vitro anti-neuroinflammatory activity of polyketides in *Phaeosphaeria poagena*: 1. Inhibitory effect on LPS-induced NO production in BV-2 microglia; MTT is a yellow dye. Succinate dehydrogenase in the mitochondria of living cells can reduce exogenous MTT to water-insoluble blue-purple crystals of formazan, which then deposit in the cells. Dead cells lack this function. After dissolving formazan in dimethyl sulfoxide (DMSO), the absorbance is measured using a microplate reader at a specific wavelength. The absorbance value is directly proportional to the number of living cells. Changes in absorbance can indirectly reflect cell viability, thereby assessing the toxicity of compounds or treatments to cells.

[0045] Quercetin was used as a positive control. The IC50 of the positive control was... 50 The value was 11.5 ± 0.4 μM, which evaluated the ability of the compound to inhibit NO production in lipopolysaccharide (LPS)-induced BV-2 microglia. In the test, compound Dinemasone D showed significant inhibitory effect on NO production, with an IC50 value of 11.5 ± 0.4 μM. 50 The value is 13.8 ± 0.4 μ M, close to the level of quercetin. This indicates that the compound Dinemasone D has anti-neuroinflammatory activity comparable to quercetin.

[0046] 2. Effects on the expression of iNOS and COX-2 proteins; To investigate its mechanism of action, Western blotting was used to detect the effects of compound Dinemasone D on the expression of iNOS and COX-2 proteins. BV-2 cells were pretreated with different concentrations of the compound (6.25, 12.5, 25 μM) for 1 h, followed by LPS stimulation for 24 h. Total protein was extracted and analyzed by SDS-PAGE electrophoresis and Western blotting. The results are as follows: Figure 14 As shown, Figure 14 The 'a' in the figure indicates that after treatment with the compound Dinemasone D, the expression levels of iNOS and COX-2 proteins showed a significant concentration-dependent downregulation trend (corrected using GAPDH as an internal reference). Figure 14 b in Figure 14 The results of quantitative statistical analysis of iNOS protein expression levels in a were obtained. Figure 14 c in Figure 14 The results of quantitative statistical analysis of COX-2 protein expression levels in group a are presented. Compared with the LPS model group, compound Dinemasone D significantly reduced the protein expression levels of iNOS and COX-2 in a concentration-dependent manner. This suggests that its anti-inflammatory effect may be achieved by inhibiting the expression of iNOS and COX-2.

[0047] 3. Molecular docking research; Molecular docking technology was used to simulate the interaction between compound Dinemasone D and iNOS (PDB ID: 4NOS) and COX-2 (PDB ID: 5F19), thereby gaining a deeper understanding of its anti-inflammatory mechanism. Figure 15 As shown, compound DinemasoneD exhibits significant affinity for both iNOS and COX-2, with binding energies of -6.8 kcal / mol, respectively. Figure 15 a) and -7.6 kcal / mol Figure 15 (b) in the middle.

[0048] It is noteworthy that the hydrogen bond interactions between the 3-OH group and Glu377, and between the 4-OH group and Trp372, allow the compound Dinemasone D to be advantageously located within the active cavity of iNOS. Figure 15 A). Furthermore, compound Dinemasone D interacts with the active site of COX-2 by forming hydrogen bonds with Ala513, Val509, and Val335 ( Figure 15 (b) in the middle.

[0049] These interactions stabilize the binding of the compound to the target protein, further supporting the mechanism of its anti-inflammatory activity at the molecular level.

[0050] In summary, the polyketide compound Dinemasone D of this invention exhibits strong anti-neuroinflammatory activity and can be developed as a promising lead compound, providing a valuable molecular template for drug research aimed at improving or treating neurodegenerative diseases.

[0051] The embodiments described above are merely illustrative of several implementations of the present invention, and while the descriptions are specific and detailed, they should not be construed as limiting the scope of the present invention. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of the present invention, and these modifications and improvements all fall within the scope of protection of the present invention. Therefore, the scope of protection of this patent should be determined by the appended claims.

Claims

1. A polyketide compound, characterized in that, The structural formulas of polyketide compounds are as follows: 。 2. The polyketide compound according to claim 1, characterized in that, The molecular formula of polyketides is C2. 12 H 16 O5 was named Dinemasone D; Polyketides have the following nuclear magnetic resonance spectral characteristics: 1 H-NMR (400 MHz, CDCl3) and 13 C-NMR (100MHz, CDCl3) data.

3. A method for preparing a polyketide compound, said method being used to prepare the polyketide compound according to claim 1 or 2, characterized in that, The polyketide compound Dinemasone D was isolated from the solid-state fermentation product of the genus Phaeosphaeria poagena.

4. The method for preparing the polyketide compound according to claim 3, wherein the method is used to prepare the polyketide compound according to claim 1, characterized in that, The isolation of the polyketide compound Dinemasone D from the solid-state fermentation product of the genus *Phaeosphaeria poagena* specifically includes the following steps: The solid fermentation product was extracted with an organic solvent, the extract was concentrated, and then extracted again with an organic solvent. The extract phase was collected. The extract phase was purified by chromatography to obtain the polyketide compound Dinemasone D.

5. The method for preparing the polyketide compound according to claim 4, wherein the method is used to prepare the polyketide compound according to claim 1, characterized in that, The solid-state fermentation product is extracted with an organic solvent, the extract is concentrated, and then extracted again with an organic solvent. The extract phase is collected. The specific steps include the following: The solid fermentation product was ultrasonically extracted three times with an equal volume of methanol. The extracts were combined and concentrated under reduced pressure to obtain the concentrated extract. The concentrated extract was extracted five times with an equal volume of ethyl acetate to obtain an ethyl acetate extract phase. The ethyl acetate extract phases were combined to obtain an ethyl acetate extract.

6. The method for preparing the polyketide compound according to claim 5, wherein the method is used to prepare the polyketide compound according to claim 1, characterized in that, The extract phase was purified by chromatographic separation to obtain the polyketide compound DinemasoneD, specifically including the following steps: The extract phase or the ethyl acetate extract obtained from the extract phase was subjected to silica gel column chromatography and eluted with a gradient of petroleum ether-acetone at volume ratios of 30:1, 20:1, 10:1, 5:1, 1:1 and 0:1 to obtain five fractions Fr.1-Fr.

5. Fr.3 was further separated into subfractions Fr.3.1-Fr.3.8 by silica gel column chromatography using a gradient elution of petroleum ether-ethyl acetate at a volume ratio of 15:1-1:

1. The polyketide compound Dinemasone D was isolated from Fr.3.5 using silica gel, dextran gel LH-20, and semi-preparative chromatography.

7. The method for preparing the polyketide compound according to claim 6, wherein the method is used to prepare the polyketide compound according to claim 1, characterized in that, The preparation of solid-state fermentation products specifically includes the following steps: S1. Preparation of solid rice culture medium: Add 40 g of rice and 60 mL of deionized water to the solid rice culture medium, seal with a breathable membrane, sterilize, and cool for later use. S2, PDB medium preparation: Add 1.05 g potato glucose broth and 30 mL deionized water to PDB medium, sterilize with ultraviolet light for 15 min after sterilization; S3. Seed culture preparation: Phaeosphaeria poagena mycelium was inoculated into PDB medium, with 1 cm² mycelium per bottle, and cultured at 28℃ and 120 rpm for 5 days. S4. Fermentation culture: Under aseptic conditions, 400 μL of seed liquid was inoculated into each of 220 500 mL Erlenmeyer flasks containing solid rice culture medium, and the mixture was statically cultured at a constant temperature of 28℃ for 35-56 days to obtain solid fermentation products.

8. The method for preparing the polyketide compound according to claim 7, wherein the method is used to prepare the polyketide compound according to claim 1, characterized in that, The chromatographic conditions for the semi-preparative chromatography were as follows: a Waters XBridge C18 column with dimensions of 19 mm × 250 mm and a diameter of 5 μm; a mobile phase of acetonitrile-water with a volume ratio of 30:70; and a retention time tR of the polyketide compound Dinemasone D of 24.4 min.

9. An application of a polyketide compound, wherein the polyketide compound is prepared by the preparation method of the polyketide compound according to any one of claims 1 to 8, and the polyketide compound is used to prepare an antineuritis drug.

Images